Targeted Medical Pharma, Inc. (TRGM) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 62 transactions totaling $356.6K, demonstrating a bearish sentiment with -$249.8K in net insider flow. The most recent transaction on Mar 4, 2016 involved a transaction of 342,500 shares valued at $17.1K.
No significant insider buying has been recorded for TRGM in the recent period.
No significant insider selling has been recorded for TRGM in the recent period.
Based on recent SEC filings, insider sentiment for TRGM is bearish with an Insider Alignment Score of 15/100 and a net flow of -$249.8K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Targeted Medical Pharma, Inc. (TRGM) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading TRGM stock, having executed 62 transactions in the past 90 days. The most active insider is Charuvastra Exemption Trust Elizabeth (Executive), who has made 4 transactions totaling $200.0K.
Get notified when executives and directors at TRGM file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Mar 4, 2016 | B. Horne William | Executive | Award | 342,500 | $0.05 | $17.1K | |
| Mar 4, 2016 | J. Dewald Maurice | Executive | Award | 200,000 | $0.05 | $10.0K | |
| Mar 4, 2016 | Giffoni Kim | Executive | Award | 547,500 | $0.05 | $27.4K | |
| Mar 4, 2016 | Samuel Silver David | Executive | Award | 575,000 | $0.05 | $28.8K | |
| Mar 4, 2016 | Neil Weems Kerry | Executive | Award | 200,000 | $0.05 | $10.0K | |
| Mar 4, 2016 | Richard Wenkart Thomas | Executive | Award | 200,000 | $0.05 | $10.0K | |
| Dec 31, 2015 | Richard Wenkart Thomas | Executive | Award | 44,058 | $0.30 | $13.2K | |
| Nov 24, 2015 | Trust Dated September 26 2008 Giffoni Family | Executive | Sale | 8,580 | $0.02 | $172 | |
| Sep 11, 2015 | Giffoni Kim | Executive | Award | 68,077 | $0.20 | $13.6K | |
| Sep 11, 2015 | B. Horne William | Executive | Award | 65,769 | $0.20 | $13.2K | |
| Jun 30, 2015 | Richard Wenkart Thomas | Executive | Award | 40,183 | $0.30 | $12.1K | |
| Jun 17, 2015 | B. Horne William | Executive | Award | 200,000 | $0.08 | $16.0K | |
| May 20, 2015 | Giffoni Kim | Executive | Award | 68,077 | $0.20 | $13.6K | |
| May 20, 2015 | B. Horne William | Executive | Award | 65,769 | $0.20 | $13.2K | |
| Nov 24, 2014 | Trust Dated September 26 2008 Giffoni Family | Executive | Purchase | 500 | $0.50 | $250 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 8 | $303.2K | 54.7% |
Award(A) | 17 | $198.1K | 35.7% |
Purchase(P) | 12 | $53.4K | 9.6% |
Will Acquisition(W) | 11 | $0 | 0.0% |
Other(J) | 5 | $0 | 0.0% |
Gift(G) | 9 | $0 | 0.0% |
Insider selling pressure at Targeted Medical Pharma, Inc. has increased, with 14 insiders executing 62 transactions across all time. Total sales of $303.2K significantly outpace purchases of $53.4K, resulting in a net outflow of $249.8K. This selling activity appears largely discretionary, which may warrant closer attention from investors.